{"title":"[终末期心力衰竭左心室辅助装置植入术围术期凝血管理:4例并文献复习]。","authors":"H X Wang, H W Wang","doi":"10.3760/cma.j.cn121090-20241128-00488","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> Exploring the management of perioperative coagulation function in patients with end-stage heart failure undergoing left ventricular assist device implantation surgery. <b>Methods:</b> Collect clinical data of four end-stage heart failure cases who underwent left ventricular assist device implantation surgery at TEDA International Cardiovascular Hospital from September to November 2023, including surgical conditions, coagulation indicators, application of blood products and coagulation drugs, and conduct literature review. <b>Results:</b> Four patients underwent left ventricular assist device implantation surgery, as well as tricuspid valve shaping and left atrial appendage closure surgery. One patient underwent mitral valve shaping surgery, while the other underwent aortic valve replacement surgery. All patients used blood products such as platelets and cryoprecipitate during the surgery. They also used clotting drugs such as fibrinogen and recombinant human coagulation factor VIIa during surgery. After returning to the intensive care unit, all patients received oral warfarin and heparin bridged anticoagulant therapy. All patients did not experience any coagulation related complications and were discharged smoothly. Currently, all patients have a good quality of life. <b>Conclusions:</b> The coagulation management of left ventricular assist device implantation surgery for end-stage heart failure is influenced by multiple factors such as etiology and surgical impact, and The management strategy presented in this paper can serve as a reference method for reducing coagulation-related complications in clinical practice.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"45 S1","pages":"47-52"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Perioperative coagulation management during left ventricular assist device implantation surgery for end-stage heart failure: four cases and literature review].\",\"authors\":\"H X Wang, H W Wang\",\"doi\":\"10.3760/cma.j.cn121090-20241128-00488\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Objective:</b> Exploring the management of perioperative coagulation function in patients with end-stage heart failure undergoing left ventricular assist device implantation surgery. <b>Methods:</b> Collect clinical data of four end-stage heart failure cases who underwent left ventricular assist device implantation surgery at TEDA International Cardiovascular Hospital from September to November 2023, including surgical conditions, coagulation indicators, application of blood products and coagulation drugs, and conduct literature review. <b>Results:</b> Four patients underwent left ventricular assist device implantation surgery, as well as tricuspid valve shaping and left atrial appendage closure surgery. One patient underwent mitral valve shaping surgery, while the other underwent aortic valve replacement surgery. All patients used blood products such as platelets and cryoprecipitate during the surgery. They also used clotting drugs such as fibrinogen and recombinant human coagulation factor VIIa during surgery. After returning to the intensive care unit, all patients received oral warfarin and heparin bridged anticoagulant therapy. All patients did not experience any coagulation related complications and were discharged smoothly. Currently, all patients have a good quality of life. <b>Conclusions:</b> The coagulation management of left ventricular assist device implantation surgery for end-stage heart failure is influenced by multiple factors such as etiology and surgical impact, and The management strategy presented in this paper can serve as a reference method for reducing coagulation-related complications in clinical practice.</p>\",\"PeriodicalId\":24016,\"journal\":{\"name\":\"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi\",\"volume\":\"45 S1\",\"pages\":\"47-52\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3760/cma.j.cn121090-20241128-00488\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3760/cma.j.cn121090-20241128-00488","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
目的探讨对接受左心室辅助装置植入手术的终末期心力衰竭患者围术期凝血功能的管理。方法:收集 4 例接受左心室辅助装置植入手术的终末期心力衰竭患者的临床资料:收集2023年9月-11月在泰达国际心血管病医院接受左心室辅助装置植入手术的4例终末期心力衰竭患者的临床资料,包括手术情况、凝血指标、血制品及凝血药物的应用情况等,并进行文献回顾。结果4例患者接受了左心室辅助装置植入手术,以及三尖瓣成形术和左房阑尾关闭术。一名患者接受了二尖瓣成形手术,另一名患者接受了主动脉瓣置换手术。所有患者在手术中都使用了血小板和低温沉淀等血液制品。手术期间,他们还使用了纤维蛋白原和重组人凝血因子 VIIa 等凝血药物。返回重症监护室后,所有患者都接受了口服华法林和肝素桥接抗凝治疗。所有患者均未出现任何与凝血相关的并发症,并顺利出院。目前,所有患者的生活质量良好。结论左心室辅助装置植入手术治疗终末期心力衰竭的凝血管理受到病因、手术影响等多种因素的影响,本文提出的管理策略可作为临床实践中减少凝血相关并发症的参考方法。
[Perioperative coagulation management during left ventricular assist device implantation surgery for end-stage heart failure: four cases and literature review].
Objective: Exploring the management of perioperative coagulation function in patients with end-stage heart failure undergoing left ventricular assist device implantation surgery. Methods: Collect clinical data of four end-stage heart failure cases who underwent left ventricular assist device implantation surgery at TEDA International Cardiovascular Hospital from September to November 2023, including surgical conditions, coagulation indicators, application of blood products and coagulation drugs, and conduct literature review. Results: Four patients underwent left ventricular assist device implantation surgery, as well as tricuspid valve shaping and left atrial appendage closure surgery. One patient underwent mitral valve shaping surgery, while the other underwent aortic valve replacement surgery. All patients used blood products such as platelets and cryoprecipitate during the surgery. They also used clotting drugs such as fibrinogen and recombinant human coagulation factor VIIa during surgery. After returning to the intensive care unit, all patients received oral warfarin and heparin bridged anticoagulant therapy. All patients did not experience any coagulation related complications and were discharged smoothly. Currently, all patients have a good quality of life. Conclusions: The coagulation management of left ventricular assist device implantation surgery for end-stage heart failure is influenced by multiple factors such as etiology and surgical impact, and The management strategy presented in this paper can serve as a reference method for reducing coagulation-related complications in clinical practice.